EUVIMEDEUVIMED entdecken
Multizentrische StudieVergleichsstudieKohortenstudieOpen Access · CC BY 4.0

Ultra-low dose superparamagnetic iron oxide nanoparticle injection for sentinel lymph node detection in breast cancer: prospective cohort study

Lovisa Sundh, Marya Alzoubi, Nizar Abu-Oddos, Sarah Båtelsson, Per Nyman, Andreas Karakatsanis iD, Staffan Eriksson, Mookaiah Ravichandran, Kian Chin, Roger Olofsson Bagge, Nushin Mirzaei, Fredrik Wärnberg iD

British Journal of Surgery · 2025

DOI: 10.1093/bjs/znaf129 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift British Journal of Surgery, 2025. Verfasst von Lovisa Sundh und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery, Region Västra Götaland, Sahlgrenska University Hospital, Gothenburg, Sweden. Hauptthemen laut MEDLINE: Breast Neoplasms, Sentinel Lymph Node, Magnetic Iron Oxide Nanoparticles, Sentinel Lymph Node Biopsy. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 19 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Swedish Breast Cancer Society, Region Västra Götaland, Swedish state and seven Swedish.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Sentinel lymph node (SLN) staging is essential in breast cancer. Superparamagnetic iron oxide nanoparticles (SPIO) is a tracer where the optimal injection technique is yet not defined. The aim was to evaluate SLN detection using 0.1 ml SPIO intradermally compared to technetium-99 m (Tc99) ± blue dye.

Method

Patients planned for breast surgery and SLN biopsy received 0.1 ml SPIO intradermally at the areolar border or over the tumour. Tc99 ± blue dye was administered per clinical routine. Magnetic, radioactive, or blue nodes were removed and analysed separately. SLN detection and numbers, concordance, and skin discoloration were analysed.

Results

A total of 216 patients were included at five hospitals. Median age was 63 years, tumour size 15.9 mm, and 91.7% underwent breast conservation. SPIO was injected a median of 12 days before surgery. SLN detection was 211/216 (97.7%; 95% c.i.: 94.7 to 99.2) and 215/216 (99.5%; 95% c.i.: 98.6 to 100.0) for SPIO and Tc99 ± blue dye (P = 0.111) respectively. In total, 403 SLNs were removed; 341 detected by SPIO and 349 by Tc99 ± blue dye. The median number of SLNs was 1 (iqr: 1–2) for both tracer methods. Among 46 SLN-positive patients, 42 were correctly staged with both tracers, two with SPIO only and two with Tc99 ± blue dye only. Skin discoloration was evaluated in 107 patients. The median discoloured area was 0 cm2 (iqr: 0–0.7) among 49 patients with the injection site surgically removed and 1.3 cm2 (iqr: 0.6–2.8) among 58 without removal.

Conclusion

An ultra-low dose of 0.1 ml intradermal injection of SPIO was non-inferior to Tc99 ± blue dye for SLN detection. Skin discoloration was limited and further reduced by removal during surgery.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsSentinel Lymph NodeMagnetic Iron Oxide NanoparticlesSentinel Lymph Node BiopsyMagnetite NanoparticlesContrast MediaHumansFemaleMiddle AgedProspective StudiesAgedInjections, IntradermalAdultTechnetiumAged, 80 and overColoring AgentsLymphatic Metastasis

Substanzen

TechnetiumMagnetite NanoparticlesColoring AgentsContrast MediaTechnetium-99

Autor:innen und Institutionen

  • Department of Surgery, Region Västra Götaland, Sahlgrenska University Hospital, Gothenburg, Sweden.
  • Department of Surgery, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
  • Section for Breast Surgery, Department of Surgery, Västmanland County Hospital, Västerås, Sweden.
  • Department of Surgery, Skaraborg Hospital, Lidköping, Sweden.
  • Section for Breast Surgery, Department of Surgical Sciences, Uppsala University Hospital, Uppsala, Sweden.
  • Department of Surgical Sciences, Uppsala University, Uppsala, Sweden.

ORCID-Profile: Andreas Karakatsanis, Fredrik Wärnberg

Förderung

  • Swedish Breast Cancer Society
  • Region Västra Götaland
  • Swedish state and seven Swedish

Zitieren

APA

Sundh, L., Alzoubi, M., Abu-Oddos, N., Båtelsson, S., Nyman, P., Karakatsanis, A., Eriksson, S., Ravichandran, M., Chin, K., Olofsson Bagge, R., Mirzaei, N., & Wärnberg, F. (2025). Ultra-low dose superparamagnetic iron oxide nanoparticle injection for sentinel lymph node detection in breast cancer: prospective cohort study. British Journal of Surgery. https://doi.org/10.1093/bjs/znaf129

Vancouver

Sundh L, Alzoubi M, Abu-Oddos N, Båtelsson S, Nyman P, Karakatsanis A, et al. Ultra-low dose superparamagnetic iron oxide nanoparticle injection for sentinel lymph node detection in breast cancer: prospective cohort study. British Journal of Surgery. 2025. doi:10.1093/bjs/znaf129

BibTeX
@article{Sundh2025,
  author = {Sundh, Lovisa and Alzoubi, Marya and Abu-Oddos, Nizar and Båtelsson, Sarah and Nyman, Per and Karakatsanis, Andreas and Eriksson, Staffan and Ravichandran, Mookaiah and Chin, Kian and Olofsson Bagge, Roger and Mirzaei, Nushin and Wärnberg, Fredrik},
  title = {Ultra-low dose superparamagnetic iron oxide nanoparticle injection for sentinel lymph node detection in breast cancer: prospective cohort study},
  journal = {British Journal of Surgery},
  year = {2025},
  doi = {10.1093/bjs/znaf129}
}
Kostenlos starten →